After the FDA approved both combination macitentan/tadalafil (Opsynvi) and the biologic therapy sotatercept (Winrevair) for ...

Cardiac output and stroke volume as measured by impedance cardiography may hold potential to predict clinical deterioration ...

Data collected on patients seen from September 1, 1996, to December 31 ... [9] Consequently, a group of pulmonary hypertension specialists initiated a voluntary collaborative survey entitled ...

Gradient Denervation Technologies, which is based in Paris, France, announced that the company’s pulmonary artery denervation ...

Research into prostacyclin analogs for the treatment of WHO Group 2 PH has been limited ... Phosphodiesterase type 5; PH: Pulmonary hypertension.

Pulmonary hypertension is classified into 5 groups based on its cause, according to the American Lung Association: This group ...

The following is a summary of "Prognostic value of non-invasive right ventricle-pulmonary artery coupling in patients with ...

Synhale has acquired telaglenastat, and is planning a Phase 2 clinical trial testing the therapy in patients with pulmonary ...

Although several Group 1 PH (Pulmonary Arterial Hypertension, "PAH”) medications have been explored in Group 2 PH, to date, no medications have been approved for its treatment. About TX45, a ...

The combination of antifibrotic therapy and pulmonary vasodilator therapy improved transplant-free survival but had no ...

Gradient Denervation Technologies announced today the company’s pulmonary denervation system has received Breakthrough Device ...